Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review - PubMed (original) (raw)

Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

Dongzhe Hong et al. Pharmacoeconomics. 2019 Jun.

Erratum in

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
Hong D, Si L, Jiang M, Shao H, Ming WK, Zhao Y, Li Y, Shi L. Hong D, et al. Pharmacoeconomics. 2019 Dec;37(12):1553. doi: 10.1007/s40273-019-00833-1. Pharmacoeconomics. 2019. PMID: 31485924

Abstract

Objective: This study aimed to systematically review cost-effectiveness studies of newer antidiabetic medications.

Methods: The PubMed/MEDLINE, EMBASE, CINAHL Plus, Cochrane Library-NHS Economic Evaluation Database (Wiley), Cochrane Library-Health Technology Assessment Database (Wiley), Cochrane Library-Database of Abstracts of Reviews of Effects (Wiley), and the Cost-Effectiveness Analysis Registry databases (from 1 January 2000 to 1 June 2018) were searched. The search strategies included the Medical Subject Heading (MeSH) term 'economics', and the MeSH entry terms 'cost', 'cost effectiveness', 'value', and 'cost utility', as well as all names for GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors. Inclusion criteria included (1) cost-effectiveness studies of the newer antidiabetic medications, including sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors; and (2) full-text publications in English. Two reviewers independently screened the titles, abstracts, and full-text articles to select studies for data extraction. Discrepancies were resolved by discussion and consensus. The quality of reporting cost-effectiveness analyses was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guideline.

Results: Among 85 studies selected, 82 clearly stated the types of diabetes model used (e.g. CORE model), and 70 studied used validated diabetes models. Seventy-four (87%) studies were funded by pharmaceutical companies, and 72 (85%) studies were conducted from a payer's perspective. Seventy-six (89%) studies presented were of good quality (20-24 CHEERS items), and nine were of moderate quality (14-19 items). Thirty studies compared newer antidiabetic medications with insulin, 3 studies compared newer antidiabetic medications with thiazolidinediones (TZDs), 15 studies compared newer antidiabetic medications with sulfonylureas, 40 studies compared new antidiabetic medications with alternative newer antidiabetic medication, and 9 studies compared other antidiabetic agents that were not included above. Newer antidiabetic medications were reported to be cost-effective in 26 of 30 (87%) studies compared with insulin, and 13 of 15 (87%) studies compared with sulfonylureas.

Conclusions: Most economic evaluations of antidiabetic medications have good reporting quality and use validated diabetes models. The newer antidiabetic medications in most of the reviewed studies were found to be cost effective, compared with insulin, TZDs, and sulfonylureas.

PubMed Disclaimer

Cited by

Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose-response meta-analysis based on animal models.
Liu X, Gu X, Zhang J, Li X, Wei X, Jiang S, Li W. Liu X, et al. J Diabetes. 2024 Sep;16(9):e13608. doi: 10.1111/1753-0407.13608. J Diabetes. 2024. PMID: 39264004 Free PMC article.
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.
Htoo PT, NajafZadeh M, Tesfaye H, Schneeweiss S, Wexler DJ, Glynn RJ, Schmedt N, Déruaz-Luyet A, Koeneman L, Paik JM, Patorno E. Htoo PT, et al. Diabetes Care. 2024 Nov 1;47(11):1900-1907. doi: 10.2337/dc24-0270. Diabetes Care. 2024. PMID: 38917305
Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
Franchi M, Pellegrini G, Avogaro A, Buzzetti G, Candido R, Cavaliere A, Consoli A, Marzona I, Mennini FS, Palcic S, Corrao G. Franchi M, et al. BMJ Open Diabetes Res Care. 2024 May 27;12(3):e003991. doi: 10.1136/bmjdrc-2023-003991. BMJ Open Diabetes Res Care. 2024. PMID: 38802266 Free PMC article.
Effects of Non-Face-to-Face Chronic Care Management on Service Utilization and Outcomes Among US Medicare Beneficiaries with Diabetes.
Hong D, Stoecker C, Shao Y, Nauman E, Fonseca V, Hu G, Bazzano AN, Kabagambe EK, Shi L. Hong D, et al. J Gen Intern Med. 2024 Aug;39(11):1985-1992. doi: 10.1007/s11606-024-08667-0. Epub 2024 Feb 21. J Gen Intern Med. 2024. PMID: 38381242 Free PMC article.
Bromocriptine and Colesevelam Hydrochloride: Novel Therapies for Type II Diabetes Mellitus.
Soileau LG, Nguyen A, Senthil A, Boullion JA, Talbot NC, Ahmadzadeh S, Shekoohi S, Kaye AD, Varrassi G. Soileau LG, et al. Cureus. 2023 Dec 7;15(12):e50138. doi: 10.7759/cureus.50138. eCollection 2023 Dec. Cureus. 2023. PMID: 38192911 Free PMC article. Review.

References

1. Pharmacoeconomics. 2016 Sep;34(9):953-66 - PubMed
1. PLoS One. 2015 Apr 07;10(4):e0121915 - PubMed
1. J Med Econ. 2015;18(10):808-20 - PubMed
1. Clinicoecon Outcomes Res. 2017 Dec 12;9:749-762 - PubMed
1. J Diabetes Complications. 2017 Dec;31(12):1719-1727 - PubMed

Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review - PubMed (original) (raw)